Trial Recruitment At Warp Speed

A leading biotechnology firm in its final stages of developing an advanced COVID-19 vaccine was preparing to initiate a substantial Phase III trial. The trial's structure was carefully coordinated with other Phase III trials supported by Operation Warp Speed. It was meticulously designed with clear objectives to ensure diverse recruitment, aiming to enroll 30,000 volunteers. The trial sites were strategically chosen to prioritize communities and demographic groups that had been severely affected by the disease, particularly focusing on individuals aged 65 and above, along with those living with underlying health conditions that put them at greater risk of COVID-19 complications.

Learn how Citeline Connect supported the fastest-recruiting trial in the operation’s history, delivering 6,432 randomizations (22% of target), over 50% within the minority population, in a record-setting 48 days.